
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
Cystic FibrosisCystic Fibrosis-related Diabetes3 moreThe purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.

Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver DiseaseLight-to-moderate Alcohol Consumption1 moreThis study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).

Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Diabetes MellitusType 22 moreSphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied. The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.

Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI
Non-alcoholic SteatohepatitisLiver Diseases3 moreThis is a prospective observational study which will recruit up to 100 paediatric participants over a period of 30 months to determine whether MRI is as accurate at detecting, distinguishing, and monitoring liver disease as current standard of care techniques such as liver biopsy and fibroscan.

Ultrasound Quantification of Liver Fat
Non-Alcoholic Fatty Liver DiseaseThe investigators plan a prospective study designed to evaluate the accuracy of a new ultrasound method for quantification of liver fat content.

Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
Nonalcoholic Fatty LiverThis study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.

The Role of Immune Semaphorins in NAFLD
Non-Alcoholic Fatty Liver DiseaseImmune Response3 moreTo goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
Non-alcoholic Steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease (MASLD)The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines. This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients...
PsoriasisNonalcoholic Fatty Liver DiseaseMain objectives 1. Establish the association of psoriasis and the presence of NAFLD in the patients with psoriasis attending dermatologic clinic center. Secondary objective Evaluate for the presence of other components metabolic syndrome in this group of patients including hypercholesterolemia, hypertension, obesity, and insulin resistance Determine if there is an association between the extent and severity of psoriasis and the presence of NAFLD. Identify an association between BMI and presence of NAFLD in people with psoriasis and use it as a predictive index for primary screening of NAFLD in psoriatic patients.

Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine...
Type 2 DiabetesPrediabetes2 more"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls. Through confirmation of different profile of BAs in T2DM, investigator will suggest modulation of specific bile acids as a new possible treatment target in patients with T2DM. Investigator also expect the specific BAs signature will be used to screen T2DM before hyperglycemia. In addition, investigator will evaluate the association between each BA species and serum total glucagon like peptide-1 (GLP-1) or fibroblast growth factor-19 (FGF-19) concentrations to determine if the specific BAs profile is related with total GLP-1 or FGF-19 concentration in serum. Investigatr also evaluates the correlation between each BA species and metabolic profiles and oxidative stress marker to find possible roles of each BA component in glucose metabolism.